Hoth Therapeutics has released a detailed update on its clinical and preclinical programs. The company is advancing four key assets, HT-001, HT-KIT, HT-ALZ, and its new GDNF-based metabolic program, while strengthening its IP portfolio and expanding research partnerships.
HT-001: Phase 2 Trial Progresses With Strong Safety Signals
HT-001 targets EGFR-inhibitor–associated rash, a common and challenging side effect in cancer care.
Recent progress:
- No dose-limiting toxicities reported so far.
- Clear improvement trends in rash severity and itching.
- Rising engagement from clinical sites with positive investigator feedback.
- More Phase 2 data expected in the coming months.
HT-KIT: Orphan Drug Program Edges Toward IND Submission
HT-KIT is designed for mastocytosis and other mast-cell–driven conditions.
Key accomplishments:
- Already granted FDA Orphan Drug Designation.
- Preclinical data shows potent KIT inhibition and strong mast-cell suppression.
- IND-enabling toxicology work nearing completion.
- Manufacturing scale-up and analytical testing underway.
- IND submission targeted for 2026, followed by first-in-human studies.
HT-ALZ: Advancing Through GLP Studies for Alzheimer’s Disease
HT-ALZ continues to move forward with supportive safety and PK data.
Latest developments:
- GLP studies underway with promising PK and biodistribution results.
- Early CNS-penetration modeling appears favorable.
- Regulatory-focused data package expected to mature in 2026.
New GDNF-Based Metabolic Program Gains Momentum
Hoth’s newest program uses GDNF to target obesity, liver fat accumulation, and broader metabolic dysfunction, areas with massive global demand.
Recent milestones:
- Study preparations initiated with the Atlanta VA Medical Center.
- Mouse procurement completed; high-fat-diet model now active.
- Aim 1 officially underway with initial results expected in 2026.
- Program supported by strong academic collaboration and new IP filings.
Strengthening IP and Expanding Partnerships
Hoth continues to build a robust IP portfolio across all programs, including:
- HT-001 mechanisms for dermatology and oncology care.
- HT-KIT formulations and manufacturing processes.
- HT-ALZ delivery technologies and CNS data.
- GDNF applications in weight-loss and hepatic health.
The company also maintains active partnerships with the Atlanta VA, neuroscience groups, and AI-driven discovery teams.
Key Milestones to Watch
- New Phase 2 data from the CLEER-001 trial for HT-001.
- Completion of HT-KIT toxicology studies and IND filing.
- Expanded GLP and PK readouts for HT-ALZ.
- Early findings from the GDNF metabolic program.
Leadership View
According to CEO Robb Knie, the pipeline is “more focused and better positioned than ever.” Each program is advancing toward meaningful clinical or preclinical inflection points.
